CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CervoMed Inc., a NASDAQ-listed clinical-stage biotechnology company developing treatments for age-related brain disorders, has closed a registered direct offering of 2.5 million shares at $4.00 per share, raising gross proceeds of $10 million. The company plans to use these funds for working capital and general corporate purposes as it advances its…